Anna Greka

And so in this way, I think we can both advance our knowledge about these monogenic diseases, build models, hopefully, with predictive capabilities.

And to your point, a lot of what we will learn about this biology, if we think that it involves

8,000 or more out of the 20,000 genes in our genome, it will, of course, serve our understanding of polygenic diseases ultimately as well.

You know, as we, you know, go deeper into this biology and we look at the combinatorial aspects of what, you know, different mutations do to human cells.

And so it's a huge aspirational problem for a whole generation, but it's a good one to work on, I would say.

Absolutely.

And I think this is going to be, you know, you mentioned the ACI presidency in the beginning of our call.

You know, this is going to be, you know, the president gets to give an address at the annual meeting in Chicago.

This is going to be one of the points I make, you know, no matter what field in biomedicine we're in.

We live in, I believe, a golden era, and we have so many tools available to us that we can really accelerate our ability to help more patients.

And, of course, this is our mandate.

The most important stakeholders for everything that we do as physician scientists are our patients, ultimately.

I feel very hopeful for the future and our ability to use these tools and to really make good on the promise of research is a public good.

And I really hope that we can advance our knowledge for the benefit of all.

And this is really an exciting time, I think, to be in this field.

And hopefully, for the younger colleagues, a time to really get excited about getting in there and getting involved and asking the big questions.

I never left.

Yeah, this is coming into 31 years now in Boston.

Yeah, I started as a Harvard undergraduate, and I'm now a full professor.

It's kind of a long but wonderful road.